ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Chrysophanol is associated with reduced inflammation and oxidative stress in sepsis-associated acute kidney injury.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting integrated cell death networks in sepsis‑associated acute kidney injury: Shared regulatory nodes and diet‑related small molecule modulation (Review).International journal of molecular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Sepsis-associated acute kidney injury (SA-AKI) is a common and severe complication in critically ill patients with high mortality, characterized by a dysregulated inflammatory response and oxidative stress. Chrysophanol (CHR), a natural anthraquinone, has demonstrated anti-inflammatory properties in other septic conditions, but its role and mechanism in SA-AKI remain unclear. This study aimed to investigate the protective effects of CHR against SA-AKI and the underlying mechanisms. Cell viability, inflammatory cytokine expression (IL-6, IL-1β, TNF-α, MCP-1, IL-10), and intracellular reactive oxygen species (ROS) levels were assessed after CHR pretreatment. An in vivo model was established using LPS method. Renal injury was evaluated through histopathology (H&E, Masson's, TUNEL staining), renal function (serum creatinine and BUN), and systemic inflammation (serum IL-6, TNF-α, IL-10). In vitro, LPS significantly reduced HK-2 cell viability and increased the production of pro-inflammatory cytokines and ROS. CHR pretreatment restored cell viability, suppressed the mRNA levels of IL-6, IL-1β, TNF-α, and MCP-1, enhanced IL-10 expression, and reduced intracellular ROS levels. In vivo, LPS-induced mice exhibited severe renal pathological damage, apoptosis, collagen deposition, and elevated serum creatinine and BUN. CHR treatment attenuate these pathological changes, reduced renal injury scores and apoptosis, and improved renal function. Furthermore, CHR significantly decreased serum levels of pro-inflammatory IL-6 and TNF-α while increasing the anti-inflammatory cytokine IL-10 in LPS mice. Chrysophanol treatment is associated with improved cell survival, reduced inflammatory cytokine expression, and decreased oxidative stress in LPS-stimulated HK-2 cells and septic mice. These associations suggest a potential protective role of chrysophanol in SA-AKI, though the underlying molecular mechanisms require further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.